[go: up one dir, main page]

WO2008149177A3 - Compositions lipidiques marines et leurs utilisations - Google Patents

Compositions lipidiques marines et leurs utilisations Download PDF

Info

Publication number
WO2008149177A3
WO2008149177A3 PCT/IB2007/003097 IB2007003097W WO2008149177A3 WO 2008149177 A3 WO2008149177 A3 WO 2008149177A3 IB 2007003097 W IB2007003097 W IB 2007003097W WO 2008149177 A3 WO2008149177 A3 WO 2008149177A3
Authority
WO
WIPO (PCT)
Prior art keywords
lipid compositions
omega
marine lipid
compositions
marine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2007/003097
Other languages
English (en)
Other versions
WO2008149177A2 (fr
Inventor
Inge Bruheim
Hogne Hallaraker
Sebastiano Banni
Mikko Griinari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aker Biomarine ASA
Original Assignee
Natural ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natural ASA filed Critical Natural ASA
Anticipated expiration legal-status Critical
Publication of WO2008149177A2 publication Critical patent/WO2008149177A2/fr
Publication of WO2008149177A3 publication Critical patent/WO2008149177A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J7/00—Phosphatide compositions for foodstuffs, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Animal Husbandry (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

La présente invention concerne de nouvelles compositions lipidiques marines comportant des triglycérides et des phospholipides riches en acides gras oméga 3. Les compositions sont caractérisées par la fourniture d'oméga 3 hautement biodisponibles, l'incorporation accrue de tissu en oméga 3 et une concentration réduite de cytokines pro-inflammatoires.
PCT/IB2007/003097 2006-05-05 2007-05-04 Compositions lipidiques marines et leurs utilisations Ceased WO2008149177A2 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US79802706P 2006-05-05 2006-05-05
US79803006P 2006-05-05 2006-05-05
US79802606P 2006-05-05 2006-05-05
US60/798,030 2006-05-05
US60/798,027 2006-05-05
US60/798,026 2006-05-05
US87209606P 2006-12-01 2006-12-01
US60/872,096 2006-12-01

Publications (2)

Publication Number Publication Date
WO2008149177A2 WO2008149177A2 (fr) 2008-12-11
WO2008149177A3 true WO2008149177A3 (fr) 2009-01-29

Family

ID=39168268

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/003097 Ceased WO2008149177A2 (fr) 2006-05-05 2007-05-04 Compositions lipidiques marines et leurs utilisations

Country Status (1)

Country Link
WO (1) WO2008149177A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008140026A1 (fr) * 2007-05-11 2008-11-20 Bizen Chemical Co., Ltd. Antagoniste inédit du récepteur des leucotriènes
ES2663714T3 (es) 2009-10-29 2018-04-16 Acasti Pharma Inc Composiciones terapéuticas concentradas en fosfolípidos
JP5872483B2 (ja) 2009-12-30 2016-03-01 ビーエイエスエフ ファーマ（コーラニッシュ）リミテッド 擬似移動床式クロマトグラフ分離方法
GB201111594D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New improved process
GB201111595D0 (en) 2011-07-06 2011-08-24 Equateq Ltd Improved process
GB201111601D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New process
GB201111589D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New modified process
GB201111591D0 (en) 2011-07-06 2011-08-24 Equateq Ltd Further new process
WO2013033618A1 (fr) 2011-09-02 2013-03-07 Arctic Nutrition As Compositions lipidiques à forte teneur en dha
GB201300354D0 (en) 2013-01-09 2013-02-20 Basf Pharma Callanish Ltd Multi-step separation process
US9428711B2 (en) 2013-05-07 2016-08-30 Groupe Novasep Chromatographic process for the production of highly purified polyunsaturated fatty acids
US8802880B1 (en) 2013-05-07 2014-08-12 Group Novasep Chromatographic process for the production of highly purified polyunsaturated fatty acids
EP2883860B1 (fr) 2013-12-11 2016-08-24 Novasep Process Procédé chromatographique de production d'acides gras polyinsaturés
EP3092218B1 (fr) 2014-01-07 2022-03-09 Novasep Process Solutions Procédé de purification d'acides aminés aromatiques
EP3709817B2 (fr) * 2017-11-17 2025-10-22 Hill's Pet Nutrition, Inc. Compositions comprenant des acides gras oméga 3 polyinsaturés et à chaîne moyenne
CN110564787B (zh) * 2019-08-02 2023-02-21 大渔华创(广州)海洋生物科技有限公司 一种富含多不饱和脂肪酸溶血磷脂组合物及其制备方法
CN110538185A (zh) * 2019-10-09 2019-12-06 广东海洋大学深圳研究院 海参磷脂在制备防治炎症药物中的应用
EP4611786A1 (fr) * 2022-11-03 2025-09-10 Exerkine Corporation Composition d'amélioration de la fertilité

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021335A1 (fr) * 1991-05-30 1992-12-10 Kabi Pharmacia Ab Phospholipides
WO1996026287A1 (fr) * 1995-02-24 1996-08-29 Goemar S.A. Procedes enzymatiques d'enrichissement en acides gras polyinsatures
WO2006054183A2 (fr) * 2004-11-17 2006-05-26 Natural Asa Phospholipides marins obtenus par synthese enzymatique

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021335A1 (fr) * 1991-05-30 1992-12-10 Kabi Pharmacia Ab Phospholipides
WO1996026287A1 (fr) * 1995-02-24 1996-08-29 Goemar S.A. Procedes enzymatiques d'enrichissement en acides gras polyinsatures
WO2006054183A2 (fr) * 2004-11-17 2006-05-26 Natural Asa Phospholipides marins obtenus par synthese enzymatique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HOSOKAWA M ET AL: "PREPARATION OF THERAPEUTIC PHOSPHOLIPIDS THROUGH PORCINE PANCREATIC PHOSPHOLIPASE A2-MEDIATED ESTERIFICATION AND LIPOZYME-MEDIATED ACIDOLYSIS", JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, SPRINGER, BERLIN, DE, vol. 72, no. 11, 1995, pages 1287 - 1291, XP008048478, ISSN: 0003-021X *

Also Published As

Publication number Publication date
WO2008149177A2 (fr) 2008-12-11

Similar Documents

Publication Publication Date Title
WO2008149177A3 (fr) Compositions lipidiques marines et leurs utilisations
WO2009055568A3 (fr) Préparations de vancomycine liposomales
WO2007090393A3 (fr) Préparation pharmaceutique
EP2054042B8 (fr) Procédés de préparation de composés biologiquement actifs sous forme de nanoparticules
WO2006117217A3 (fr) Nouvelle utilisation de spiegelmers
WO2010043415A3 (fr) Compositions de protéine de lactosérum, procédés et utilisations
WO2007101551A3 (fr) Complexes phospholipidiques de curcumine présentant une biodisponibilité améliorée
WO2008066899A3 (fr) Formulations de nanoparticules et procédés de préparation et d'utilisation de celles-ci
ZA200810741B (en) Methodes for the preparation of biologically active compounds in nanoparticulate form
WO2007066232A3 (fr) Sels d'acides gras et procedes de fabrication et d'utilisation de ces derniers
ZA200804830B (en) Oil-in-water formulation of avermectins
EP2039366A4 (fr) Composition contenant un peptide comme principe actif
WO2006131591A3 (fr) Forme posologique destinee a etre administree par voie orale
WO2008085221A3 (fr) Utilisation thérapeutique de cellules exprimant cd31
WO2008136865A3 (fr) (s)-n-stéréoisomères d'analogues de 4,5-époxy-morphinanium saturés en 7,8
EP1932533A4 (fr) Composition pour l'amélioration du métabolisme des lipides corporels
WO2007070613A3 (fr) Analogues de la rifamycine et leurs utilisations
UA88030C2 (ru) Композиция, которая содержит омега-3-жирные кислоты и омега-6-жирные кислоты, для лечения синдрома сухого глаза
EP2335698B8 (fr) Préparation pharmaceutique solide contenant des ingrédients actifs séparés par une frontière interne
WO2008107771A3 (fr) 2',3'-di-o-acyl-5-fluoronucléosides
CA2556520A1 (fr) Composes a base de chrome et d'acide gras et methodes de production et d'utilisation connexes
WO2010025011A8 (fr) Formulations de canfosfamide et leur préparation
ZA200710664B (en) Processes for the preparation of docetaxel
EP1879013A4 (fr) Procede d'elaboration de formulations medicamenteuses auto-emulsionnantes
WO2008136852A3 (fr) Méthodes et compositions se rapportant à la structure et à la fonction de apobec3g

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07825397

Country of ref document: EP

Kind code of ref document: A2

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC

122 Ep: pct application non-entry in european phase

Ref document number: 07825397

Country of ref document: EP

Kind code of ref document: A2